Phuturdex › Diseases › Anti-neutrophil cytoplasmic antibody-associated vasculitis
Drugs in development · updated 30 October 2026
Anti-neutrophil cytoplasmic antibody-associated vasculitis: drugs in development
As of 30 October 2026 there are 29 active clinical trials (recruiting or ongoing, phases I–III) on 35 drugs for anti-neutrophil cytoplasmic antibody-associated vasculitis. 21 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BDB001EIK1001 | III | 1 | NCT07168161 |
| CC-97540 | I–II | 1 | NCT07388277 |
| Descartes-08 | I–II | 1 | NCT07089121 |
| FT839 | I–II | 1 | NCT07800871 |
| NKX019 | I–II | 1 | NCT06733935 |
| NM8074 | II | 1 | NCT06226662 |
| Povetacicept | I–II | 1 | NCT05732402 |
| Tarperprumig | II | 1 | NCT07160608 |
| Telitacicept | I–II | 1 | NCT06656962 |
| VIS954 | II | 1 | NCT07904806 |
| ADI-001 | I | 1 | NCT06375993 |
| FKC289 | I | 1 | NCT06285279 |
| FT819 | I | 1 | NCT06308978 |
| KYV-101 | I | 1 | NCT06152172 |
| OL-108 | I | 1 | NCT06980597 |
| QT-019C | I | 1 | NCT07315087 |
| SC291 | I | 1 | NCT06294236 |
| BCT301 | Early I | 1 | NCT07301164 |
| CD19 | Early I | 1 | NCT06548607 |
| MTS109 | Early I | 1 | NCT07526350 |
| V001-BCMA | Early I | 1 | NCT07339540 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | III | 8 | NCT07168161 |
| PrednisonePredinisone, Cortancyl | III | 4 | NCT07168161 |
| RituximabRuxience, Rituxan | III | 4 | NCT07168161 |
| AvacopanTavneos®, Vynpenta (previously AvacopanChemoCentryx)® | III | 1 | NCT07373262 |
| AzathioprineImuran, Jayempi® | III | 1 | NCT07168161 |
| Mabthera | III | 1 | NCT03323476 |
| Mycophenolate MofetilMycophenolate, Cellcept | III | 1 | NCT03323476 |
| PioglitazoneActos, Pioglitazone Accord® | III | 1 | NCT05946564 |
| TocilizumabTociluzumab, Avtozma | III | 1 | NCT04871191 |
| TofacitinibXeljanz®, Inijaq® | III | 1 | NCT04871191 |
| FludarabineFludara, FLUDARABIN | I–II | 5 | NCT06733935 |
| IptacopanLNP023, Fabhalta® | II | 1 | NCT06388941 |
| SparsentanFilspari® | II | 1 | NCT05630612 |
| BendamustineBendamustin, Bedamustine | I | 1 | NCT06308978 |
Sorted by most advanced phase and number of active trials.
All 35 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Churg-Strauss syndrome 7 drugs
- Granulomatosis with polyangiitis 36 drugs
- Rheumatoid arthritis 130 drugs
- Systemic lupus erythematosus 178 drugs
- Vasculitis 35 drugs
- Pemphigus 9 drugs
- Rheumatic Diseases 30 drugs
- Psoriatic arthritis 48 drugs
- Ankylosing spondylitis 31 drugs
- Arthritis, Juvenile 39 drugs
- Spondylarthritis 27 drugs
- Polymyalgia rheumatica 30 drugs
Broader categories
- Vascular disease 16 drugs
- Skin disease 34 drugs
- Skin and connective tissue diseases 3 drugs
- Immune System Diseases 54 drugs
- Cardiovascular disease 71 drugs
- Autoimmune disease 94 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D056648 “Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis”. Prevalence: Orphanet.